Tuberous-sclerosis complex-related cell signaling in the pathogenesis of lung cancer

Diagnostic Pathology

Volumn 9, Issue 1, 2014, Pages

  Fuchs, Angela ^a   König, Katharina ^b   Heukamp, Lukas C ^b   Fassunke, Jana ^b   Kirfel, Jutta ^a   Huss, Sebastian ^c   Becker, Albert J ^a   Büttner, Reinhard ^b   Majores, Michael ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

EGFR; Hamartin; Lung cancer; TSC; Tuberin; Tuberous sclerosis complex

Indexed keywords

MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TUBERIN; TUBEROUS SCLEROSIS COMPLEX 1 PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; PHYSIOLOGY; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VERY ELDERLY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENES, ERBB-1; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMALL CELL LUNG CARCINOMA; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84897571546     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-9-48     Document Type: Article

References (36)

1. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981, 66:1191-1308.
2. Pinchot SN, Holen K, Sippel RS, Chen H. Carcinoid tumors. Oncologist 2008, 13:1255-1269. 10.1634/theoncologist.2008-0207, 2901509, 19091780.
3. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. Tumours of the lung. Pathology and Genetics of Tumours of the Lung Pleura Thymus and Heart 2004, 10-12. Geneva: WHO Press.
4. Larsen JE, Cascone T, Gerber DE, Heymach JV, Minna JD. Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J 2011, 17:512-527. 10.1097/PPO.0b013e31823e701a, 3381956, 22157296.
5. Heukamp LC, Wolf J, Buttner R. [Molecular diagnostics of lung cancer for treatment stratification]. Internist (Berl) 2011, 52:146. 148-150, 152-144, 10.1007/s00108-010-2698-y, 21298249.
6. Sobol RE, Astarita RW, Hofeditz C, Masui H, Fairshter R, Royston I, Mendelsohn J. Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody. J Natl Cancer Inst 1987, 79:403-407.
7. Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS, Wistuba. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007, 13:2890-2896. 10.1158/1078-0432.CCR-06-3043, 17504988.
8. Papadimitrakopoulou V. Development of Pi3k/Akt/Mtor pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. J Thorac Oncol 2012, 7:1314-1326.
9. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9:550-562. 10.1038/nrc2664, 19629070.
10. Otto C, Csanadi A, Fisch P, Werner M, Kayser G. Molecular modeling and description of a newly characterized activating mutation of the EGFR gene in non-small cell lung cancer. Diagn Pathol 2012, 7:146. 10.1186/1746-1596-7-146, 3523061, 23088930.
11. Xiong Y, Bai Y, Leong N, Laughlin TS, Rothberg PG, Xu H, Nong L, Zhao J, Dong Y, Li T. Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies. Diagn Pathol 2013, 8:27. 10.1186/1746-1596-8-27, 3635899, 23419122.
12. Hengstschlager M, Rodman DM, Miloloza A, Hengstschlager-Ottnad E, Rosner M, Kubista M. Tuberous sclerosis gene products in proliferation control. Mutat Res 2001, 488:233-239. 10.1016/S1383-5742(01)00058-8, 11397651.
13. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006, 355:1345-1356. 10.1056/NEJMra055323, 17005952.
14. Kudo M. mTOR inhibitor for the treatment of hepatocellular carcinoma. Dig Dis 2011, 29:310-315. 10.1159/000327565, 21829022.
15. Gibbons JJ, Abraham RT, Yu K. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol 2009, 36(Suppl 3):S3-S17.
16. Knowles MA, Hornigold N, Pitt E. Tuberous sclerosis complex (TSC) gene involvement in sporadic tumours. Biochem Soc Trans 2003, 31:597-602.
17. Rosner M, Freilinger A, Hengstschlager M. The tuberous sclerosis genes and regulation of the cyclin-dependent kinase inhibitor p27. Mutat Res 2006, 613:10-16. 10.1016/j.mrrev.2006.03.001, 16713332.
18. Takamochi K, Ogura T, Suzuki K, Kawasaki H, Kurashima Y, Yokose T, Ochiai A, Nagai K, Nishiwaki Y, Esumi H. Loss of heterozygosity on chromosomes 9q and 16p in atypical adenomatous hyperplasia concomitant with adenocarcinoma of the lung. Am J Pathol 1941-1948, 2001:159.
19. Takamochi K, Ogura T, Yokose T, Ochiai A, Nagai K, Nishiwaki Y, Suzuki K, Esumi H. Molecular analysis of the TSC1 gene in adenocarcinoma of the lung. Lung Cancer 2004, 46:271-281. 10.1016/j.lungcan.2004.05.001, 15541811.
20. Liang MC, Ma J, Chen L, Kozlowski P, Qin W, Li D, Goto J, Shimamura T, Hayes DN, Meyerson M, Kwiatkowski DJ, Wong KK. TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. Oncogene 2010, 29:1588-1597. 10.1038/onc.2009.452, 2841700, 19966866.
21. Zimmer S, Kahl P, Buhl TM, Steiner S, Wardelmann E, Merkelbach-Bruse S, Buettner R, Heukamp LC. Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling. J Cancer Res Clin Oncol 2009, 135:723-730. 10.1007/s00432-008-0509-9, 19002495.
22. Becker AJ, Lobach M, Klein H, Normann S, Nothen MM, von Deimling A, Mizuguchi M, Elger CE, Schramm J, Wiestler OD, Blumcke I. Mutational analysis of TSC1 and TSC2 genes in gangliogliomas. Neuropathol Appl Neurobiol 2001, 27:105-114. 10.1046/j.0305-1846.2001.00302.x, 11437991.
23. Rosenthal A, Coutelle O, Craxton M. Large-scale production of DNA sequencing templates by microtitre format PCR. Nucleic Acids Res 1993, 21:173-174. 10.1093/nar/21.1.173, 309083, 8441614.
24. Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006, 12:839-844. 10.1158/1078-0432.CCR-05-1846, 16467097.
25. Bilello KS, Murin S, Matthay RA. Epidemiology, etiology, and prevention of lung cancer. Clin Chest Med 2002, 23:1-25. 10.1016/S0272-5231(03)00057-1, 11901905.
26. Ekman S, Wynes MW, Hirsch FR. The mTOR pathway in lung cancer and implications for therapy and biomarker analysis. J Thorac Oncol 2012, 7:947-953. 10.1097/JTO.0b013e31825581bd, 22588151.
27. Conde E, Angulo B, Tang M, Morente M, Torres-Lanzas J, Lopez-Encuentra A, Lopez-Rios F, Sanchez-Cespedes M. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. Clin Cancer Res 2006, 12:710-717. 10.1158/1078-0432.CCR-05-1362, 16467080.
28. Downward J, Parker P, Waterfield MD. Autophosphorylation sites on the epidermal growth factor receptor. Nature 1984, 311:483-485. 10.1038/311483a0, 6090945.
29. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003, 284:31-53. 10.1016/S0014-4827(02)00098-8, 12648464.
30. Zheng S, Du Y, Chu H, Chen X, Li P, Wang Y, Ma Y, Wang H, Zang W, Zhang G, Zhao G. Analysis of MAT3 gene expression in NSCLC. Diagn Pathol 2013, 8:166. 10.1186/1746-1596-8-166, 3853379, 24107548.
31. Beljan Perak R, Durdov MG, Capkun V, Ivcevic V, Pavlovic A, Soljic V, Peric M. IMP3 can predict aggressive behaviour of lung adenocarcinoma. Diagn Pathol 2012, 7:165. 10.1186/1746-1596-7-165, 3533585, 23190601.
32. Dhillon T, Mauri FA, Bellezza G, Cagini L, Barbareschi M, North BV, Seckl MJ. Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer. J Thorac Oncol 2010, 5:314-319. 10.1097/JTO.0b013e3181ce6604, 20093977.
33. Lionello M, Blandamura S, Loreggian L, Ottaviano G, Giacomelli L, Marchese-Ragona R, Velardita C, Staffieri A, Marioni G. High mTOR expression is associated with a worse oncological outcome in laryngeal carcinoma treated with postoperative radiotherapy: a pilot study. J Oral Pathol Med 2012, 41:136-140. 10.1111/j.1600-0714.2011.01083.x, 21943204.
34. Back JH, Kim AL. The expanding relevance of nuclear mTOR in carcinogenesis. Cell Cycle 2011, 10:3849-3852. 10.4161/cc.10.22.18329, 3356804, 22067472.
35. Bachmann RA, Kim JH, Wu AL, Park IH, Chen J. A nuclear transport signal in mammalian target of rapamycin is critical for its cytoplasmic signaling to S6 kinase 1. J Biol Chem 2006, 281:7357-7363. 10.1074/jbc.M512218200, 16407298.
36. Liu J, Brown RE. Morphoproteomics demonstrates activation of mammalian target of rapamycin pathway in papillary thyroid carcinomas with nuclear translocation of MTOR in aggressive histological variants. Mod Pathol 2011, 24:1553-1559. 10.1038/modpathol.2011.121, 21822208.